Scott Eliasof
Affiliations: | Broad Institute, Cambridge, MA, United States |
Area:
retina, glutamate transporters, chemical biologyGoogle:
"Scott Eliasof"Mean distance: 13.45 (cluster 11) | S | N | B | C | P |
Parents
Sign in to add mentor| Frank S. Werblin | grad student | 1986-1992 | UC Berkeley |
| Craig E. Jahr | post-doc | OHSU | |
| Rory Curtis | research scientist | 2000-2001 | Millennium Pharmaceuticals |
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Metcalf C, Svenson S, Hwang J, et al. (2019) Discovery of a Novel Cabazitaxel Nanoparticle-Drug Conjugate (CRLX522) with Improved Pharmacokinetic Properties and Anticancer Effects using a β-Cyclodextrin-PEG Copolymer-Based Delivery Platform. Journal of Medicinal Chemistry |
| Chao J, Lin J, Frankel P, et al. (2017) Pilot trial of CRLX101 in patients with advanced, chemotherapy-refractory gastroesophageal cancer. Journal of Gastrointestinal Oncology. 8: 962-969 |
| Rey S, Schito L, Wouters BG, et al. (2017) Targeting Hypoxia-Inducible Factors for Antiangiogenic Cancer Therapy. Trends in Cancer. 3: 529-541 |
| O'Connor LO, Wang AT, Jones D, et al. (2017) Abstract B32: CRLX101, an investigational camptothecin-containing nanoparticle-drug conjugate, combined with DDR agents provides a novel approach to increasing therapeutic index Molecular Cancer Research. 15 |
| Metcalf C, Poll Dvd, Zhao L, et al. (2017) Abstract PR10: Significant improvements in therapeutic index for conjugated payloads using a nanoparticle-drug conjugate (NDC) platform to provide sustained drug release and potentially improved anticancer effects Cancer Research. 77 |
| Metcalf CA, Poll Dvd, Zhao L, et al. (2017) Abstract 5135: Sustained and controlledin vivotherapeutic levels of drug payloads in tumors using two separate drug combination platforms: Antibody nanoparticle-drug conjugates and multi-drug nanoparticle-drug conjugates, with the potential for improved drug combinability and anticancer effects Cancer Research. 77: 5135-5135 |
| Tian X, Nguyen M, Foote HP, et al. (2016) CRLX101, a nanoparticle-drug conjugate containing camptothecin, improves rectal cancer chemoradiotherapy by inhibiting DNA repair and HIF-1α. Cancer Research |
| Keefe SM, Hoffman-Censits J, Cohen RB, et al. (2016) Efficacy of the nanoparticle-drug conjugate CRLX101 in combination with bevacizumab in metastatic renal cell carcinoma: results of an investigator-initiated phase I-IIa clinical trial. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. 27: 1579-85 |
| Svenson S, Case RI, Cole RO, et al. (2016) Tumor Selective Silencing Using an RNAi-Conjugated Polymeric Nanopharmaceutical. Molecular Pharmaceutics |
| Chao J, Lin J, Frankel PH, et al. (2016) Pilot trial of CRLX101 in patients (pts) with advanced, chemotherapy-refractory gastroesophageal cancer (GEC). Journal of Clinical Oncology. 34: 44-44 |